Omeros (NASDAQ:OMER – Get Free Report) and Curaleaf (OTCMKTS:CURLF – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability.
Profitability
This table compares Omeros and Curaleaf’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Omeros | N/A | N/A | -55.49% |
| Curaleaf | -19.50% | -15.57% | -4.74% |
Valuation & Earnings
This table compares Omeros and Curaleaf”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Omeros | N/A | N/A | -$156.82 million | ($2.02) | -4.19 |
| Curaleaf | $1.34 billion | 0.99 | -$215.42 million | ($0.32) | -6.16 |
Omeros has higher earnings, but lower revenue than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
48.8% of Omeros shares are owned by institutional investors. Comparatively, 0.0% of Curaleaf shares are owned by institutional investors. 12.9% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current recommendations for Omeros and Curaleaf, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Omeros | 1 | 1 | 2 | 1 | 2.60 |
| Curaleaf | 0 | 1 | 0 | 1 | 3.00 |
Omeros presently has a consensus target price of $33.67, indicating a potential upside of 298.19%. Given Omeros’ higher probable upside, equities research analysts plainly believe Omeros is more favorable than Curaleaf.
Risk and Volatility
Omeros has a beta of 2.39, indicating that its share price is 139% more volatile than the S&P 500. Comparatively, Curaleaf has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.
Summary
Omeros beats Curaleaf on 9 of the 13 factors compared between the two stocks.
About Omeros
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
About Curaleaf
Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
